Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies

scientific article

Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2014PLoSO...997229D
P356DOI10.1371/JOURNAL.PONE.0097229
P932PMC publication ID4018276
P698PubMed publication ID24820481
P5875ResearchGate publication ID262265436

P50authorHendrik StreeckQ28032204
Margaret E. AckermanQ57012155
Dan H. BarouchQ60489346
Galit AlterQ88683228
Musie GhebremichaelQ89849219
Anne-Sophie DugastQ90440217
P2093author name stringTodd J Suscovich
Hualin Li
Joseph Nkolola
Ying Chan
Michelle Hoffner
Anna Licht
P2860cites workAntibody-dependent cell-mediated cytotoxicity against influenza virus-infected cellsQ28270714
Antibody neutralization and escape by HIV-1Q29547345
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetQ29547347
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Immune-correlates analysis of an HIV-1 vaccine efficacy trialQ29617377
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesQ30498394
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersQ33444658
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individualsQ33526340
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Q33647300
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.Q33693391
Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infectionQ33834852
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cellsQ33844334
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challengeQ33852768
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroQ33853775
Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaquesQ33966586
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Q34185625
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyQ34630446
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.Q52841139
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesQ57226425
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc SialylationQ57253538
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251Q64378954
HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progressionQ71396764
Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDSQ78678676
Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapyQ34647680
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LQ35012462
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individualsQ35037803
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesQ35101333
Control of HIV-1 infection by soluble factors of the immune responseQ35752416
A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionQ35876233
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoQ36414891
Is autoimmunity a component of natural immunity to HIV?Q36447138
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaquesQ37033311
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmQ37247974
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.Q37347813
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG doseQ37528015
The role of antibodies in HIV vaccinesQ37700725
Fc receptor regulation of protective immunity against Chlamydia trachomatisQ37872443
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaquesQ39265150
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralizationQ39723388
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cellsQ40274328
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.Q40291422
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllersQ40659603
Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patientsQ41689302
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infectionQ45740971
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infectionQ45744790
Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccineQ45745469
Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count.Q45987356
Fc receptor but not complement binding is important in antibody protection against HIV.Q46545827
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
P304page(s)e97229
P577publication date2014-05-12
P1433published inPLOS OneQ564954
P1476titleLack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies
P478volume9

Reverse relations

cites work (P2860)
Q35920037Animal models in HIV-1 protection and therapy
Q26991572Antibody responses to envelope glycoproteins in HIV-1 infection
Q59352288Antibody-dependent cellular cytotoxicity in HIV infection
Q37512871Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
Q34204325Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
Q89803119Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)
Q26782237Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1
Q58763247Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Q40794254Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model.
Q52580309First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Q39108716HIV antibodies for treatment of HIV infection
Q36252656HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans
Q52598776HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
Q35778333Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance
Q64263004Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
Q38998925Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies
Q48234349Low doses of IgG from atopic individuals can modulate in vitro IFN-γ production by human intra-thymic TCD4 and TCD8 cells: An IVIg comparative approach
Q64066666Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
Q38719420Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner
Q64115950Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response
Q90411103Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development
Q40052007Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity
Q52660832Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.
Q37510242Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
Q91582856Neutralization and beyond: Antibodies and HIV-1 acquisition
Q38748193New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.
Q28068018Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization
Q33638320Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.
Q35569901Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life
Q51743315Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.
Q30238730Survivors Remorse: antibody-mediated protection against HIV-1.
Q35985519Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
Q64060305The Antibodiome-Mapping the Humoral Immune Response to HIV
Q37113972The role of Fc receptors in HIV prevention and therapy
Q55411165Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.
Q38764543Use of broadly neutralizing antibodies for HIV-1 prevention
Q50034030Virus-Like-Vaccines against HIV.
Q35641144What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
Q40063734What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection